Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Casirivimab/imdevimab vs usual care alone Adverse events: grades 3 and 4 by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs usual care alone Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo  · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.32 [0.07, 1.47] | 1 study · 263 participants | Low |
Bamlanivimab vs placebo Adverse events: all grades · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.99 [0.66, 1.5] | 1 study · 257 participants | Low |
Bamlanivimab vs placebo Serious adverse events · non‐hospitalised individuals with COVID‐19 SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.51 [0.02, 12.47] | 1 study · 257 participants | Low |
Bamlanivimab/etesevimab vs placebo Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane | RR 0.05 [0, 0.81] | 1 study · 1035 participants | Low |
Aspirin (ASA) vs vitamin K antagonist (VKA) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 3 [0.12, 73.24] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs vitamin K antagonist (VKA) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs low molecular weight heparin (LMWH) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1 [0.06, 15.81] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1.23 [0.49, 3.08] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 7.71 [0.97, 61.44] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 6.97 [0.36, 134.11] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1.42 [0.35, 5.78] | 2 studies · 781 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1 [0.06, 15.89] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1.2 [0.53, 2.72] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 9 [0.49, 166.17] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs vitamin K antagonist (VKA) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 0.57 [0.24, 1.33] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 0.33 [0.01, 8.1] | 1 study · 439 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 2.32 [0.91, 5.93] | 1 study · 439 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 8.96 [0.49, 165.42] | 1 study · 439 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 0.33 [0.03, 3.17] | 1 study · 439 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 2 [0.18, 21.9] | 1 study · 440 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1.7 [0.8, 3.63] | 1 study · 440 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 9 [0.49, 166.17] | 1 study · 440 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs vitamin K antagonist (VKA) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1 [0.25, 3.95] | 1 study · 440 participants | Very low |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) Symptomatic deep vein thrombosis ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 5 [0.31, 79.94] | 1 study · 8 participants | Very low |
Aspirin (ASA) vs vitamin K antagonist (VKA) Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 7 [0.36, 134.72] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs vitamin K antagonist (VKA) Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents: 6 months follow‐up Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 6 [0.73, 49.43] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs vitamin K antagonist (VKA) All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 0.5 [0.05, 5.47] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs vitamin K antagonist (VKA) Symptomatic deep vein thrombosis · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 0.71 [0.35, 1.44] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs vitamin K antagonist (VKA) Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | RR 1 [0.25, 3.95] | 1 study · 440 participants | Very low |
Aspirin (ASA) vs vitamin K antagonist (VKA) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Azithromycin vs placebo or standard of care alone All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4 to 9) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 0.98 [0.9, 1.06] | 4 studies · 8600 participants | High |
Azithromycin vs placebo or standard of care alone All initial symptoms resolved (asymptomatic) at day 14 · people with mild disease (WHO scale 1 to 3) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 1.03 [0.95, 1.12] | 1 study · 138 participants | Low |
Azithromycin vs placebo or standard of care alone Duration to symptom resolution · people with mild disease (WHO scale 1 to 3) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Azithromycin vs placebo or standard of care alone Quality of life at longest · people with mild disease (WHO scale 1 to 3) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Azithromycin vs placebo or standard of care alone Any adverse events during the study period · people with mild disease (WHO scale 1 to 3) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Azithromycin vs placebo or standard of care alone Serious adverse events during the study period · people with mild disease (WHO scale 1 to 3) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 2 studies · 454 participants | Very low |
Azithromycin vs placebo or standard of care alone Cardiac arrhythmias during the study period · people with mild disease (WHO scale 1 to 3) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Azithromycin vs placebo or standard of care alone Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28 · people with moderate to severe disease (WHO scale 4 to 9) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 0.95 [0.87, 1.03] | 1 study · 7311 participants | Moderate |
Azithromycin vs placebo or standard of care alone Improvement of clinical status: participants discharged alive at day 28 · people with moderate to severe disease (WHO scale 4 to 9) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | RR 0.96 [0.84, 1.11] | 3 studies · 8172 participants | Moderate |
Azithromycin vs placebo or standard of care alone Quality of life at longest · people with moderate to severe disease (WHO scale 4 to 9) Antibiotics for the treatment of COVID‐19 (2021) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |